Color blindness affects millions worldwide, with Blue Cone Monochromacy (BCM) being a rare form of this condition, affecting about one in every 100,000 people. BCM is a genetic disorder resulting ...

7m8-L-opsin), a novel gene therapy product candidate being developed as a potential single intravitreal (IVT) administration for blue cone monochromacy (BCM) by delivering a functional copy of the ...

ADVM-062, a novel gene therapy candidate, received orphan drug designation from the FDA for the treatment of blue cone monochromacy, according to a press release from Adverum Biotechnologies.

7m8-L-opsin), a novel gene therapy product candidate being developed as a potential single intravitreal (IVT) administration for blue cone monochromacy (BCM) by delivering a functional copy of the ...